Clincosm LogoSign in Get a demo

refractory small lymphocytic lymphoma

Showing 1 - 21 of 21
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

Suspended
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Seattle (procedure, drug, biological, radiation)

Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 26, 2022

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duarte, California
  • +2 more
Oct 7, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jul 14, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +4 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 22, 2022

Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Completed
  • Loss of Chromosome 17p
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 4, 2022

Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Dose combination 1-1
  • +5 more
  • (no location specified)
Nov 1, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
Aug 10, 2021

B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic

Terminated
  • B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
  • +16 more
  • Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
May 28, 2021

Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma Trial in Portland (drug, other, biological)

Completed
  • Anemia
  • +13 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Apr 29, 2021

Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma Trial in Houston (Trabectedin, Venetoclax)

Withdrawn
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Mar 11, 2020

Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma Trial in Salt Lake City,

Completed
Has Results
  • Prolymphocytic Leukemia
  • +13 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +14 more
  • Salt Lake City, Utah
  • +4 more
Jan 17, 2020

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in United States (procedure, drug,

Completed
Has Results
  • Acute Lymphoblastic Leukemia
  • +25 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +7 more
  • Aurora, Colorado
  • +5 more
Dec 17, 2019

B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p Trial in Seattle, Milwaukee (procedure, drug, other,

Completed
Has Results
  • B-Cell Prolymphocytic Leukemia
  • +20 more
  • Allogeneic Bone Marrow Transplantation
  • +14 more
  • Seattle, Washington
  • +1 more
May 31, 2019